New perspectives on targeted therapy in ovarian cancer

References

• SankaranarayananRFerlayJWorldwide burden of gynaecological cancer: the size of the problemBest Pract Res Clin Obstet Gynaecol200620220722516359925
   PubMed Web of Science ®Google Scholar
• GrulichAESwerdlowAJHeadJMarmotMGCancer mortality in African and Caribbean migrants to England and WalesBr J Cancer19926659059111419634
   PubMed Web of Science ®Google Scholar
• WhittemoreASHarrisRItnyreJCollaborative Ovarian Cancer GroupCharacteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancerAm J Epidemiol199213610121212201476143
   PubMed Web of Science ®Google Scholar
• DalyMObramsGIEpidemiology and risk assessment for ovarian cancerSemin Oncol19982532552649633839
   PubMed Web of Science ®Google Scholar
• ParkinDMMuirCSCancer Incidence in Five Continents Comparability and quality of dataIARC Sci Publ1992120451731284606
   PubMedGoogle Scholar
• ChiDSEisenhauerELZivanovicOImproved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigmGynecol Oncol20091141263119395008
   PubMed Web of Science ®Google Scholar
• HerrinVEThigpenJTHigh-dose chemotherapy in ovarian carcinomaSemin Oncol19992619910510073566
   PubMed Web of Science ®Google Scholar
• SonodaYManagement of early ovarian cancerOncology (Williston Park)200418334335615065703
   PubMed Web of Science ®Google Scholar
• McGuireWPHoskinsWJBradyMFCyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancerN Engl J Med19963341167494563
   PubMed Web of Science ®Google Scholar
• NeijtJPEngelholmSATuxenMKExploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancerJ Clin Oncol200018173084309210963636
   PubMed Web of Science ®Google Scholar
• BookmanMABradyMFMcGuireWPEvaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer IntergroupJ Clin Oncol20092791419142519224846
   PubMed Web of Science ®Google Scholar
• KatsumataNYasudaMIsonishiSJapanese Gynecologic Oncology GroupLong-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trialLancet Oncol201314101020102623948349
   PubMed Web of Science ®Google Scholar
• HowellSBPfeifleCLWungWEIntraperitoneal cisplatin with systemic thiosulfate protectionAnn Intern Med19829768458516890785
   PubMed Web of Science ®Google Scholar
• MarkmanMRowinskyEHakesTPhase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group studyJ Clin Oncol1992109148514911355523
   PubMed Web of Science ®Google Scholar
• ArmstrongDKBundyBWenzelLGynecologic Oncology GroupIntraperitoneal cisplatin and paclitaxel in ovarian cancerN Engl J Med20063541344316394300
   PubMed Web of Science ®Google Scholar
• TewariDSillMMonkBPhase III randomized clinical trial of cisplatin plus paclitaxel vs the non-platinum chemotherapy doublet of topotecan plus paclitaxel in women with recurrent, persistent, or advanced cervical carcinoma: A Gynecologic Oncology Group studyGynecol Oncol20131e2
   Google Scholar
• JaabackKJohnsonNLawrieTAIntraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancerCochrane Database Syst Rev201111CD00534022071822
   PubMed Web of Science ®Google Scholar
• VaughanSCowardJIBastRCJrRethinking ovarian cancer: recommendations for improving outcomesNat Rev Cancer2011111071972521941283
   PubMed Web of Science ®Google Scholar
• BurgerRASillMWMonkBJGreerBESoroskyJIPhase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group StudyJ Clin Oncol200725335165517118024863
   PubMed Web of Science ®Google Scholar
• CannistraSAMatulonisUAPensonRTPhase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancerJ Clin Oncol200725335180518618024865
   PubMed Web of Science ®Google Scholar
• BurgerRABradyMFBookmanMAGynecologic Oncology GroupIncorporation of bevacizumab in the primary treatment of ovarian cancerN Engl J Med2011365262473248322204724
   PubMed Web of Science ®Google Scholar
• PerrenTJSwartAMPfistererJICON7 InvestigatorsA phase 3 trial of bevacizumab in ovarian cancerN Engl J Med2011365262484249622204725
   PubMed Web of Science ®Google Scholar
• LedermannJARajaFAFotopoulouCESMO Guidelines Working GroupNewly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201324Suppl 6vi24vi3224078660
   PubMed Web of Science ®Google Scholar
• GourleyCMcCaviganAPerrenTMolecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumabPresented at: 2014 ASCO Annual MeetingMay 30–June 3, 2014Chicago, Illinois Abstract 5502
   Google Scholar
• AghajanianCBlankSVGoffBAOCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancerJ Clin Oncol201230172039204522529265
   PubMed Web of Science ®Google Scholar
• Pujade-LauraineEHilpertFWeberBBevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trialJ Clin Oncol201432131302130824637997
   PubMed Web of Science ®Google Scholar
• HallMGourleyCMcNeishITargeted anti-vascular therapies for ovarian cancer: current evidenceBr J Cancer2013108225025823385789
   PubMed Web of Science ®Google Scholar
• LearyAThe PI3K/Akt/mTOR Pathway in Ovarian Cancer: Biological Rationale and Therapeutic OpportunitiesRijeka, CroatiaIntech2013 Available from: http://dx.doi.org/10.5772/54170Accessed December 1, 2014
   Google Scholar
• AravantinosGPectasidesDBevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic reviewJ Ovarian Res201475724864163
   PubMed Web of Science ®Google Scholar
• ColemanRLDuskaLRRamirezPTPhase 1–2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancerLancet Oncol201112121109111721992853
   PubMed Web of Science ®Google Scholar
• GotliebWHAmantFAdvaniSIntravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled studyLancet Oncol201213215416222192729
   PubMed Web of Science ®Google Scholar
• LedermannJAHackshawAKayeSRandomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancerJ Clin Oncol201129283798380421859991
   PubMed Web of Science ®Google Scholar
• Du BoisAKristensenGRay-CoquardIAGO-OVAR 12: a randomized placebo-controlled GCIG/ENGOT-Intergroup phase III trial of standard frontline chemotherapy/−nintedanib for advanced ovarian cancer [abstract]Int J Gynecol Cancer201323suppl 1LBA1
   Google Scholar
• CarmelietPJainRKAngiogenesis in cancer and other diseasesNature2000407680124925711001068
   PubMed Web of Science ®Google Scholar
• MonkBJPovedaAVergoteIA phase III, randomized, double-blind trial of weekly paclitaxel plus the angiopoietin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer [abstract]: TRINOVA-1Eur J Cancer2013493LBA:41
   Google Scholar
• DavidsonBASecordAAProfile of pazopanib and its potential in the treatment of epithelial ovarian cancerInt J Womens Health2014136 :289–300.
   Google Scholar
• FriedlanderMHancockKCRischinDA Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancerGynecol Oncol20101191323720584542
   PubMed Web of Science ®Google Scholar
• du BoisAFloquetAKimJWIncorporation of pazopanib in maintenance therapy of ovarian cancerJ Clin Oncol201432303374338225225436
   PubMed Web of Science ®Google Scholar
• MendelDBLairdADXinXIn vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationshipClin Cancer Res20039132733712538485
   PubMed Web of Science ®Google Scholar
• BiagiJJOzaAMChalchalHIA phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group StudyAnn Oncol201122233534020705911
   PubMed Web of Science ®Google Scholar
• BaumannKHdu BoisAMeierWA phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapyAnn Oncol20122392265227122377563
   PubMed Web of Science ®Google Scholar
• CamposSMPensonRTMatulonisUA phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinomaGynecol Oncol2013128221522022885865
   PubMed Web of Science ®Google Scholar
• MateiDSillMWLankesHAActivity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trialJ Clin Oncol2011291697521098323
   PubMed Web of Science ®Google Scholar
• HerzogTJScambiaGKimBGA randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinomaGynecol Oncol20131301253023591401
   PubMed Web of Science ®Google Scholar
• ThompsonDSDudleyBSBismayerJAPaclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: A randomized phase II study of the Sarah Cannon Research InstitutePresented at: 2013 ASCO Annual MeetingMay 31–June 4, 2014Chicago, Illinois Abstract 5513
   Google Scholar
• MatulonisUABerlinSIvyPCediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancerJ Clin Oncol200927335601560619826113
   PubMed Web of Science ®Google Scholar
• LedermannJAPerrenTJRajaFARandomized double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trialEuropean J of Cancer201349Suppl 3 Abstract 10
   Google Scholar
• ChoKRShihIeMOvarian cancerAnnu Rev Pathol20094128731318842102
   PubMed Web of Science ®Google Scholar
• GershensonDMSunCCBodurkaDRecurrent low-grade serous ovarian carcinoma is relatively chemoresistantGynecol Oncol20091141485219361839
   PubMed Web of Science ®Google Scholar
• SchmelerKMSunCCBodurkaDCNeoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneumGynecol Oncol2008108351051418155273
   PubMed Web of Science ®Google Scholar
• LiJFadareOXiangLKongBZhengWOvarian serous carcinoma: recent concepts on its origin and carcinogenesisJ Hematol Oncol20125822405464
   PubMed Web of Science ®Google Scholar
• BellDBerchuckABirrerMCancer Genome Atlas Research NetworkIntegrated genomic analyses of ovarian carcinomaNature2011474735360961521720365
   PubMed Web of Science ®Google Scholar
• FarleyJBradyWEVathipadiekalVSelumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 studyLancet Oncol201314213414023261356
   PubMed Web of Science ®Google Scholar
• GershensonDMThe life and times of low-grade serous carcinoma of the ovaryPresented at: 2013 ASCO Annual MeetingMay 31–June 4, 2014Chicago, Illinois
   Google Scholar
• BastRCJrMolecular approaches to personalizing management of ovarian cancerAnn Oncol201122Suppl 8viii5viii1522180401
   PubMedGoogle Scholar
• KojimaKKonoplevaMMcQueenTO’BrienSPlunkettWAndreeffMMdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemiaBlood20061083993100016543464
   PubMed Web of Science ®Google Scholar
• KimAUedaYNakaTEnomotoTTherapeutic strategies in epithelial ovarian cancer. Journal of experimental and clinical cancer researchCR (East Lansing, Mich)20123114
   Google Scholar
• KurmanRJShihIeMMolecular pathogenesis and extraovarian origin of epithelial ovarian cancer – shifting the paradigmHum Pathol201142791893121683865
   PubMed Web of Science ®Google Scholar
• AnglesioMSGeorgeJKulbeHIL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancerClin Cancer Res20111782538254821343371
   PubMed Web of Science ®Google Scholar
• StanyMPVathipadiekalVOzbunLIdentification of novel therapeutic targets in microdissected clear cell ovarian cancersPLoS ONE201167e2112121754983
   PubMed Web of Science ®Google Scholar
• AlexandreJRay-CoquardISelleFGINECOMucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experienceAnn Oncol201021122377238120494964
   PubMed Web of Science ®Google Scholar
• AnglesioMSKommossSTolcherMCMolecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomasJ Pathol2013229111112022899400
   PubMed Web of Science ®Google Scholar
• SyriosJBanerjeeSKayeSBAdvanced epithelial ovarian cancer: from standard chemotherapy to promising molecular pathway targets – where are we now?Anticancer Res20143452069207724778008
   PubMed Web of Science ®Google Scholar
• BookmanMADarcyKMClarke-PearsonDBoothbyRAHorowitzIREvaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology GroupJ Clin Oncol200321228329012525520
   PubMed Web of Science ®Google Scholar
• McAlpineJNWiegandKCVangRHER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapyBMC Cancer20099143320003286
   PubMed Web of Science ®Google Scholar
• BehbakhtKSillMWDarcyKMPhase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group studyGynecol Oncol20111231192621752435
   PubMed Web of Science ®Google Scholar
• FarmerHMcCabeNLordCJTargeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature2005434703591792115829967
   PubMed Web of Science ®Google Scholar
• BryantHESchultzNThomasHDSpecific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature2005434703591391715829966
   PubMed Web of Science ®Google Scholar
• VirágLSzabóCThe therapeutic potential of poly(ADP-ribose) polymerase inhibitorsPharmacol Rev200254337542912223530
   PubMed Web of Science ®Google Scholar
• AshworthAA synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repairJ Clin Oncol200826223785379018591545
   PubMed Web of Science ®Google Scholar
• AntoniouAPharoahPDNarodSAverage risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studiesAm J Hum Genet20037251117113012677558
   PubMed Web of Science ®Google Scholar
• WalshTCasadeiSLeeMKMutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencingProc Natl Acad Sci U S A201110844180321803722006311
   PubMed Web of Science ®Google Scholar
• BellDBerchuckABirrerMCancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinomaNature2011474735360961521720365
   PubMed Web of Science ®Google Scholar
• TanDSRothermundtCThomasK“BRCAness” syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutationsJ Clin Oncol200826345530553618955455
   PubMed Web of Science ®Google Scholar
• PenningtonKPWalshTHarrellMIGermline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomasClin Cancer Res201420376477524240112
   PubMed Web of Science ®Google Scholar
• MuraiJHuangSYDasBBTrapping of PARP1 and PARP2 by Clinical PARP InhibitorsCancer Res201272215588559923118055
   PubMed Web of Science ®Google Scholar
• FongPCBossDSYapTAInhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriersN Engl J Med2009361212313419553641
   PubMed Web of Science ®Google Scholar
• FongPCYapTABossDSPoly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free intervalJ Clin Oncol201028152512251920406929
   PubMed Web of Science ®Google Scholar
• AudehMWCarmichaelJPensonRTOral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialLancet2010376973724525120609468
   PubMed Web of Science ®Google Scholar
• GelmonKATischkowitzMMackayHOlaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised studyLancet Oncol201112985286121862407
   PubMed Web of Science ®Google Scholar
• KayeSBLubinskiJMatulonisUPhase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly(ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancerJ Clin Oncol201230437237922203755
   PubMed Web of Science ®Google Scholar
• LedermannJHarterPGourleyCOlaparib maintenance therapy in platinum-sensitive relapsed ovarian cancerN Engl J Med2012366151382139222452356
   PubMed Web of Science ®Google Scholar
• LedermannJHarterPGourleyCOlaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trialLancet Oncol201415885286124882434
   PubMed Web of Science ®Google Scholar
• EversBDrostRSchutESelective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatinClin Cancer Res200814123916392518559613
   PubMed Web of Science ®Google Scholar
• RottenbergSJaspersJEKersbergenAHigh sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsProc Natl Acad Sci U S A200810544170791708418971340
   PubMed Web of Science ®Google Scholar
• RajanACarterCAKellyRJA phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumorsClin Cancer Res20121882344235122371451
   PubMed Web of Science ®Google Scholar
• KhanOAGoreMLoriganPA phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumoursBr J Cancer2011104575075521326243
   PubMed Web of Science ®Google Scholar
• SamolJRansonMScottESafety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I studyInvest New Drugs20123041493150021590367
   PubMed Web of Science ®Google Scholar
• LeeJMHaysJLAnnunziataCMPhase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analysesJ Natl Cancer Inst20141066dju08924842883
   PubMedGoogle Scholar
• LiuJFlemingGFTolaneySMA phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with the antiangiogenic cediranib (AZD2171) in recurrent ovarian or triple-negative breast cancerPresented at: 2011 ASCO Annual MeetingJune 3–7, 2014Chicago, Illinois Abstract 5028
   Google Scholar
• SandhuSKSchelmanWRWildingGThe poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trialLancet Oncol201314988289223810788
   PubMed Web of Science ®Google Scholar
• LordCJAshworthAMechanisms of resistance to therapies targeting BRCA-mutant cancersNat Med201319111381138824202391
   PubMed Web of Science ®Google Scholar
• TebbuttNPedersenMWJohnsTGTargeting the ERBB family in cancer: couples therapyNat Rev Cancer201313966367323949426
   PubMed Web of Science ®Google Scholar
• LafkyJMWilkenJABaronATMaihleNJClinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancerBiochim Biophys Acta20081785223226518291115
   PubMed Web of Science ®Google Scholar
• SecordAABlessingJAArmstrongDKPhase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group studyGynecol Oncol2008108349349918191993
   PubMed Web of Science ®Google Scholar
• SchilderRJSillMWChenXPhase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group StudyClin Cancer Res200511155539554816061871
   PubMed Web of Science ®Google Scholar
• VergoteIBJimenoAJolyFRandomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup studyJ Clin Oncol201432432032624366937
   PubMed Web of Science ®Google Scholar
• BookmanMADarcyKMClarke-PearsonDBoothbyRAHorowitzIREvaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology GroupJ Clin Oncol200321228329012525520
   PubMed Web of Science ®Google Scholar
• FarleyJFuchiujiSDarcyKMAssociations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group StudyGynecol Oncol2009113334134719272639
   PubMed Web of Science ®Google Scholar
• GordonMSMateiDAghajanianCClinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation statusJ Clin Oncol200624264324433216896006
   PubMed Web of Science ®Google Scholar
• KayeSBPooleCJDańska-BidzińskaAA randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancerAnn Oncol201324114515223002282
   PubMed Web of Science ®Google Scholar
• DaviesSHolmesALomoLHigh incidence of ErbB3, ErbB4, and MET expression in ovarian cancerInt J Gynecol Pathol201433440241024901400
   PubMed Web of Science ®Google Scholar
• TannerBHasencleverDSternKErbB-3 predicts survival in ovarian cancerJ Clin Oncol200624264317432316896008
   PubMed Web of Science ®Google Scholar
• SchoeberlBFaberACLiDAn ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activationCancer Res20107062485249420215504
   PubMed Web of Science ®Google Scholar
• ShengQLiuXFlemingEAn activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cellsCancer Cell201017329831020227043
   PubMed Web of Science ®Google Scholar
• BalkwillFMantovaniAInflammation and cancer: back to Virchow?Lancet2001357925553954511229684
   PubMed Web of Science ®Google Scholar
• MadhusudanSMuthuramalingamSRBraybrookeJPStudy of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancerJ Clin Oncol200523255950595916135466
   PubMed Web of Science ®Google Scholar
• BrownERCharlesKAHoareSAA clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancerAnn Oncol20081971340134618325912
   PubMed Web of Science ®Google Scholar
• CowardJKulbeHChakravartyPInterleukin-6 as a therapeutic target in human ovarian cancerClin Cancer Res20111517 (18):6083–6096.
   Google Scholar
• HamanishiJMandaiMIkedaTEfficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancerPresented at: 2014 ASCO Annual MeetingMay 30–June 3, 2014Chicago, Illinois Abstract 5511
   Google Scholar
• BrahmerJRTykodiSSChowLQSafety and activity of anti-PD-L1 antibody in patients with advanced cancerN Engl J Med2012366262455246522658128
   PubMed Web of Science ®Google Scholar
• MiottiSCanevariSMénardSCharacterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificityInt J Cancer19873932973032434438
   PubMed Web of Science ®Google Scholar
• KalliKRObergALKeeneyGLFolate receptor alpha as a tumor target in epithelial ovarian cancerGynecol Oncol2008108361962618222534
   PubMed Web of Science ®Google Scholar
• ChenYLChangMCHuangCYSerous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-responseMol Oncol20126336036922265591
   PubMed Web of Science ®Google Scholar
• ToffoliGRussoAGalloAExpression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancerInt J Cancer19987921211269583724
   PubMed Web of Science ®Google Scholar
• ArmstrongDKWhiteAJWeilSCPhillipsMColemanRLFarletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancerGynecol Oncol2013129345245823474348
   PubMed Web of Science ®Google Scholar
• ElitLKonnerJArmstrongDKA randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or refractory relapsed ovarian cancerPresented at: 2013 ASCO Annual MeetingMay 31–June 4, 2014Chicago, Illinois Abstract TPS255
   Google Scholar
• NaumannRWColemanRLBurgerRAPRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum resistant ovarian cancerJ Clin Oncol201129343s Abstract 5045.
   Google Scholar
• WernerHWeinsteinDBentovISimilarities and differences between insulin and IGF-I: structures, receptors, and signalling pathwaysArch Physiol Biochem20081141172218465355
   PubMedGoogle Scholar
• FürstenbergerGSennHJInsulin-like growth factors and cancerLancet Oncol20023529830212067807
   PubMed Web of Science ®Google Scholar
• BruchimIWernerHTargeting IGF-1 signaling pathways in gynecologic malignanciesExpert Opin Ther Targets201317330732023294364
   PubMed Web of Science ®Google Scholar
• BuckEGokhalePCKoujakSCompensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancerMol Cancer Ther20109102652266420924128
   PubMed Web of Science ®Google Scholar